Restore RP and Optic Nerve Atrophy Vision

01/10/2025

When you or someone you love is living with retinitis pigmentosa (RP), one of the first questions that comes to mind is: “Will there ever be a cure?”

22/09/2025

Why Laser Eye Surgery Is Not Recommended for Retinitis Pigmentosa Patients？

Laser refractive surgery only reshapes the cornea in the front of the eye, not the retina in the back. So why would people with RP—a retinal disease—be advised against it?

24/08/2025

Preventing Blindness with iPS Cells

22/08/2025

Did You Know? – Ultrasound for Glaucoma

Most people know ultrasound as the technology used to see babies before birth. But did you know doctors are now exploring ultrasound as a treatment for eye diseases like glaucoma?

21/08/2025

Mesenchymal Stem Cell-Derived Exosomes in Ophthalmology:
A Comprehensive Review

In recent years, mesenchymal stem cell (MSC) therapy has attracted considerable attention for its potential in treating ophthalmic diseases. While MSCs possess remarkable regenerative, reparative, and immunomodulatory properties, MSC-based therapies still face key limitations, particularly with respect to biocompatibility, tissue pe*******on, and targeted ocular delivery. To address these challenges, researchers have increasingly turned their focus toward MSC-derived exosomes.

Exosomes are nano-sized vesicles that share many of the therapeutic properties of their parent MSCs, including anti-inflammatory, anti-apoptotic, tissue-repairing, neuroprotective, and immunomodulatory effects. Importantly, MSC-derived exosomes may offer advantages as drug-delivery vehicles, as they are capable of penetrating biological barriers—such as the blood-brain barrier—suggesting potential efficacy in crossing the blood-retinal barrier as well. In addition, their cargo is protected from degradation, enhancing stability and increasing bioavailability in ocular tissues.
The following is the original scientific paper published in Pharmaceutics by MDPI.

Over the past decade, the field of mesenchymal stem cell (MSC) therapy has exhibited rapid growth. Due to their regenerative, reparatory, and immunomodulatory capacities, MSCs have been widely investigated as therapeutic agents in the cell-based treatment of chronic ophthalmic pathologies. However,....

21/08/2025

The Future of Non Invasive Eye Care

For patients with optic nerve damage caused by glaucoma or retinal disorders, the need for safe, effective, and accessible solutions continues to grow. Fortunately, rapid progress in medical technology and biotechnology is ushering in a new era of non-invasive eye care—offering gentler, more convenient, and more holistic alternatives to surgery or traditional drug-based treatments.

16/08/2025

How Nasal Conditions Can Influence Eye Pressure: What You Need to Know

In glaucoma, intraocular pressure (IOP) is affected by aqueous humor drainage through the trabecular meshwork and Schlemm’s canal.

Nasal or sinus inflammation generally does not directly block aqueous humor drainage, so it usually has minimal effect on true eye pressure.

However, chronic sinus inflammation might cause orbital congestion or mild venous pressure changes, which can subtly influence IOP in susceptible individuals.

Nasal sprays (especially decongestants like oxymetazoline) can raise IOP in patients with glaucoma, because they cause vasoconstriction and sometimes increase venous pressure in the eye.

Conversely, antihistamines typically have minimal effect on eye pressure.

Coughing, sneezing, or straining due to nasal congestion can temporarily raise eye pressure.

Nasal surgery or trauma can, in rare cases, alter orbital pressure dynamics, which may affect IOP readings temporarily.

10/08/2025

Therapeutic Potential of UC-MSCs in Retinitis Pigmentosa

1. Neuroprotection Through Paracrine Signaling

2. Anti-inflammatory and Immunomodulatory Effects

3. Support for Photoreceptor and Retinal Pigment Epithelium (RPE) Function

4. Early Clinical Evidence of Visual Function Improvement

07/08/2025

Scientific evidence supporting the benefits of electrical stimulation for glaucoma patients with progressive vision loss: https://pmc.ncbi.nlm.nih.gov/articles/PMC8969331/?fbclid=IwY2xjawMBfUBleHRuA2FlbQIxMQABHrllzkzhS7FbpUDU3phZzmEhtYhdGEkU5R7wS_8kTI8jwk3etBO_wIVx7foD_aem_9TfxQ6gYXa5L38a8bMR6EA

The retrospective study provides real-world evidence for long-term clinical efficacy of electrical optic nerve stimulation (ONS) in glaucoma with progressive vision loss. Seventy glaucoma patients (45 to 86 y) with progressive vision loss despite ...

07/08/2025

Optic nerve regeneration: Intranasal Stem Cell Delivery Outperforms Traditional Methods

One of the most exciting aspects of intranasal stem cell therapy is how it stacks up against traditional delivery methods. Each route of administration has its advantages and limitations—but intranasal delivery offers a uniquely effective and patient-friendly option for targeting the optic nerve and central nervous system.

06/08/2025

How Intranasal Umbilical Cord Stem Cell Therapy Supports Optic Nerve Regeneration?

Umbilical cord stem cell–derived therapies, particularly in the form of exosomes, offer a multi-pronged approach to healing the optic nerve. These microscopic messengers carry a complex cargo of neuroprotective and regenerative molecules that work together to repair damage, restore function, and protect the nerve from further degeneration.

05/08/2025

How Intranasal Umbilical Cord Stem Cell Therapy May Regenerate the Optic Nerve?

Intranasal administration of umbilical cord stem cell-derived therapies—especially exosomes or conditioned media—is an emerging method showing potential for optic nerve regeneration.